Please assess the completion status of the following clinical trial:

Trial Title: Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-50 years~* MTBI subjects: evidence of closed head injury; Glasgow Coma Score 13-15; loss of consciousness \< 30 minutes; post-traumatic amnesia \< 24 hours; Abbreviated Injury Score \</= 3 for any body region; absence of focal lesions on head CT scan~* Orthopedic Injury subjects: evidence of traumatic injury, other than head; Abbreviated Injury Score \</= 3 for any body region~* does not require hospitalization for injuries~* visual acuity and hearing adequate to participate in testing~* fluent in either English or Spanish~Exclusion Criteria:~* Abbreviated Injury Score \> 3 for any body region~* any type of penetrating injury~* history of significant pre-existing disease or systemic injuries~* history of schizophrenia or bipolar disorder~* blood alcohol \> 200 mL/dL~* left-handed~* existing contraindications for MRI~* claustrophobia~* pregnancy~* exclusions related to atorvastatin, including currently taking any statin drug (atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin), no longer taking a statin drug but history of use within the last six months, previously taking any statin drug at any time but now discontinued due to side effects, taking any medication with known interactions with atorvastatin (cyclosporine, fibric acid derivative, erythromycin, clarithromycin, combination of ritonavir plus saquinavir or lopinavir, niacin in doses exceeding multivitamin dosage, or azole antifungals), active liver disease, history of unexplained persistent elevation of serum transaminases, and hypersensitivity to any component of atorvastatin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- MTBI subjects randomized to drug (Type: EXPERIMENTAL): Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the treatment arm of the phase II drug trial of atorvastatin. These subjects will receive a daily weight-based dose of atorvastatin 1mg/kg (up to 80 mg) for seven days and started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving a placebo.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol.
- MTBI subjects randomized to placebo (Type: PLACEBO_COMPARATOR): Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the placebo arm of the phase II drug trial of atorvastatin. These subjects will receive a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).